Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Several other research firms also recently issued reports on MCRB. The Goldman Sachs Group lowered their price objective on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a research note on Friday, March 14th. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Thursday, March 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Seres Therapeutics Stock Performance

Shares of MCRB traded up $0.04 during trading hours on Thursday, reaching $0.58. The stock had a trading volume of 1,052,651 shares, compared to its average volume of 3,265,080. The stock has a market capitalization of $101.23 million, a PE ratio of -2.52 and a beta of 2.54. Seres Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.53. The company’s 50-day moving average is $0.73 and its two-hundred day moving average is $0.79.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors have recently modified their holdings of MCRB. Millennium Management LLC lifted its holdings in Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after buying an additional 788,762 shares during the period. Jane Street Group LLC lifted its stake in shares of Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares during the period. Northern Trust Corp boosted its position in shares of Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 44,461 shares in the last quarter. Geode Capital Management LLC grew its stake in Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after purchasing an additional 121,793 shares during the period. Finally, Avantax Advisory Services Inc. grew its stake in Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the period. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.